IQWiG: Tafinlar/Mekinist Benefit 'Considerable' In Men With Melanoma, But Still Better In Women
This article was originally published in Scrip
Germany's HTA body IQWiG has declared that there is "an indication of a considerable added benefit for men" of the combination of Novartis' Tafinlar and Mekinist (dabrafenib and trametinib).
You may also be interested in...
NICE – the HTA body for England and Wales – has recommended that Novartis's Zykadia (ceritinib) be available on the NHS, but only at a discount. Novartis tells Scrip that with the imminent arrival of the UK's new Cancer Drugs Fund (CDF), there are concerns that access to new cancer drugs will become even more difficult.
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.